NasdaqGS - Nasdaq Real Time Price USD

CytomX Therapeutics, Inc. (CTMX)

Compare

1.0900

-0.0100

(-0.91%)

At close: December 20 at 4:00:02 PM EST

1.0798

-0.01

(-0.94%)

After hours: December 20 at 5:17:01 PM EST

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks 5 days ago

CTMX
-0.91%
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.

Zacks 9 days ago

CSTL

SPRO
-4.30%
CTMX
-0.91%
Grifols Stock Declines After Brookfield Drops Buyout Offer

Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.

Zacks 23 days ago

GRFS

BAM

SPRO
-4.30%
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s we

GlobeNewswire 24 days ago

CTMX
-0.91%
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

Data from a late-stage study shows that treatment with a three-drug combo involving AZN's Truqap benefits patients with an aggressive form of prostate cancer.

Zacks 24 days ago

AZN

CSTL

CTMX
-0.91%
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.

Zacks 29 days ago

CTMX
-0.91%
SPRO
-4.30%
CSTL
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.

Zacks last month

GRFS

BAM

CTMX
-0.91%
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround

CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

CTMX
-0.91%
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.

Zacks last month

AZN

SPRO
-4.30%
CSTL
CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations

CytomX Therapeutics ( NASDAQ:CTMX ) Third Quarter 2024 Results Key Financial Results Revenue: US$33.4m (up 27% from 3Q...

Simply Wall St. last month

CTMX
-0.91%
Q3 2024 CytomX Therapeutics Inc Earnings Call

Q3 2024 CytomX Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents last month

CTMX
-0.91%
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

CytomX Therapeutics Inc (CTMX) reports increased revenue and positive clinical progress, despite higher operating costs and ongoing development challenges.

GuruFocus.com last month

CTMX
-0.91%
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 143.75% and 76.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

CTMX
-0.91%
CytomX Therapeutics: Q3 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. AP) — CytomX Therapeutics Inc. CTMX) on Thursday reported third-quarter profit of $5.8 million.

Associated Press Finance last month

CTMX
-0.91%
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. - - Phase 1 study of CX-2051 (EpCAM PROBODY® ADC) in advanced colorectal cancer (CRC) is currently in the fifth dose escalation cohort. Initial data anticipated in the first half of 2025. - - Phase 1 study of CX-801 (interferon alpha-2b PROBODY® cytokine) as monotherapy and in combination with KEYTRUDA® is ongoing with a primary focus in melanoma. Initial data ant

GlobeNewswire last month

CTMX
-0.91%
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report third quarter financial results on Thursday, November 7, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from th

GlobeNewswire last month

CTMX
-0.91%
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with potential broad applicability in both traditionally immune-oncology sensitive as well as insensitive (c

GlobeNewswire 3 months ago

CTMX
-0.91%
CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. H.C. Wainwright 26th Annual Global Investment ConferenceDate: Wednesday, September 11, 2024 Formal Presentation: 12:30 p.m. ET Location: New York, NY 2024 Cantor Global Healthcare ConferenceDate: Thursday, September 19, 2024F

GlobeNewswire 3 months ago

CTMX
-0.91%
CytomX Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

CytomX Therapeutics ( NASDAQ:CTMX ) Second Quarter 2024 Results Key Financial Results Revenue: US$25.1m (up 1.6% from...

Simply Wall St. 4 months ago

CTMX
-0.91%
CytomX Therapeutics: Q2 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. AP) — CytomX Therapeutics Inc. CTMX) on Thursday reported a loss of $6.5 million in its second quarter.

Associated Press Finance 4 months ago

CTMX
-0.91%

Performance Overview

Return	CTMX	S&P 500
YTD	-29.68%	+24.34%
1-Year	-22.70%	+24.38%
3-Year	-82.94%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Grifols Stock Declines After Brookfield Drops Buyout Offer

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Q3 2024 CytomX Therapeutics Inc Earnings Call

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates

CytomX Therapeutics: Q3 Earnings Snapshot

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

CytomX Therapeutics: Q2 Earnings Snapshot

Performance Overview